Comparative Pharmacology
Head-to-head clinical analysis: APREMILAST versus ZORYVE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APREMILAST versus ZORYVE.
APREMILAST vs ZORYVE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apremilast is a small-molecule inhibitor of phosphodiesterase 4 (PDE4), which leads to increased intracellular levels of cyclic adenosine monophosphate (cAMP). This modulates the production of pro-inflammatory and anti-inflammatory cytokines, resulting in decreased expression of TNF-α, IL-23, and other inflammatory mediators, and increased IL-10.
ZORYVE (roflumilast) is a selective phosphodiesterase-4 (PDE4) inhibitor. It inhibits the degradation of cyclic AMP (cAMP), leading to increased intracellular cAMP levels, which reduces the release of pro-inflammatory cytokines and mediators from various immune cells (e.g., neutrophils, eosinophils, macrophages).
30 mg orally twice daily, after an initial titration: 10 mg in the morning on day 1, 10 mg in the morning and evening on day 2, 10 mg in the morning and 20 mg in the evening on day 3, 20 mg in the morning and 20 mg in the evening on day 4, 20 mg in the morning and 30 mg in the evening on day 5, then 30 mg twice daily thereafter.
Topical: Apply once daily to affected areas. For plaque psoriasis, use 0.3% cream; for seborrheic dermatitis, use 0.3% foam.
None Documented
Clinical Note
moderateApremilast + Gatifloxacin
"Apremilast may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateApremilast + Rosoxacin
"Apremilast may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateApremilast + Levofloxacin
"Apremilast may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateApremilast + Trovafloxacin
"Apremilast may increase the neuroexcitatory activities of Trovafloxacin."
None Documented
6-9 hours (mean ~6.5 h) in healthy adults; no clinically significant accumulation with once-daily dosing.
Terminal elimination half-life is approximately 28 hours; steady-state achieved within 2 weeks with once-daily dosing.
58% renal (39% as unchanged drug, 19% as metabolites), 39% fecal (9% as unchanged drug, 30% as metabolites). Total recovery 97%.
Fecal (approximately 90% of absorbed dose as unchanged drug and metabolites), renal (approximately 10% as metabolites).
Category D/X
Category C
PDE4 Inhibitor
PDE4 Inhibitor